•
Sep 30, 2020
Viking Therapeutics Q3 2020 Earnings Report
Reported financial results for the third quarter of 2020 and provided a corporate update.
Key Takeaways
Viking Therapeutics reported a net loss of $9.3 million, or $0.13 per share, for the third quarter ended September 30, 2020. The company's balance sheet remains strong with $255.3 million in cash, cash equivalents and short-term investments.
Phase 2b VOYAGE study evaluating VK2809 for the treatment of NASH is ongoing.
Phase 1 trial evaluating VK0214 for the treatment of X-ALD is underway.
New data from VK2809 Phase 2 trial was highlighted during a podium presentation at EASL 2020.
Balance sheet remains strong with approximately $255 million in cash.